Supplementary Table 1. ACR20, ACR50, and ACR70 response rates by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
ACR20, % (n/N) [95% CI]			
1	56.8 (21/37) [39.5, 72.9]	66.7 (36/54) [52.5, 78.9]	38.5 (10/26) [20.2, 59.4]
3	69.4 (25/36) [51.9, 83.7]	70.4 (38/54) [56.4, 82.0]	26.9 (7/26) [11.6, 47.8]
6	73.5 (25/34) [55.6, 87.1]	81.5 (44/54) [68.6, 90.8]	60.0 (6/10) [26.2, 87.8]
9	71.4 (15/21) [47.8, 88.7]	82.5 (33/40) [67.2, 92.7]	-
12	77.8 (14/18) [52.4, 93.6]	78.9 (30/38) [62.7, 90.5]	-
ACR50, % (n/N) [95% CI]			
1	29.7 (11/37) [15.9, 47.0]	27.8 (15/54) [16.5, 41.6]	7.7 (2/26) [1.0, 25.1]
3	55.6 (20/36) [38.1, 72.1]	50.0 (27/54) [36.1, 63.9]	11.5 (3/26) [2.5, 30.2]
6	61.8 (21/34) [43.6, 77.8]	59.3 (32/54) [45.0, 72.4]	40.0 (4/10) [12.2, 73.8]
9	47.6 (10/21) [25.7, 70.2]	62.5 (25/40) [45.8, 77.3]	-
12	61.1 (11/18) [35.8, 82.7]	65.8 (25/38) [48.7, 80.4]	-

ACR70, % (n/N)
[95% CI]

1	13.5 (5/37) [4.5, 28.8]	5.6 (3/54) [1.2, 15.4]	7.7 (2/26) [1.0, 25.1]
3	25.0 (9/36) [12.1, 42.2]	20.4 (11/54) [10.6, 33.5]	3.8 (1/26) [0.1, 19.6]
6	44.1 (15/34) [27.2, 62.1]	37.0 (20/54) [24.3, 51.3]	0.0 (0/10) [0.0, 30.9]
9	42.9 (9/21) [21.8, 66.0]	45.0 (18/40) [29.3, 61.5]	-
12	38.9 (7/18) [17.3, 64.3]	52.6 (20/38) [35.8, 69.0]	-

ACR, American College of Rheumatology; BID, twice daily; FAS, full analysis set; CI, confidence interval; N, number of evaluable patients at time point of interest; n, number of patients with response.

Supplementary Table 2. Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score by treatment sequence in the Mexican Phase 3 study population over time (FAS, no imputation)

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
Change from baseline in DAS28-4(ESR), mean [95% CI] (N)			
1	-1.07 [-1.6, -0.6] (10)	-1.31 [-1.8,-0.8] (21)	-1.06 [-1.7, -0.4] (14)
3	-2.43 [-2.9, -1.9] (34)	-2.16 [-2.5, -1.8] (49)	-1.03 [-1.5, -0.6] (26)
6	-2.20 [-2.8, -1.6] (33)	-2.54 [-2.9, -2.2] (51)	-1.37 [-2.3, -0.5] (10)
9	-1.96 [-2.9, -1.0] (10)	-2.49 [-2.9, -2.1] (21)	-
12	-2.39 [-3.0, -1.8] (17)	-2.68 [-3.2, -2.1] (36)	-
Change from baseline in HAQ-DI, mean [95% CI] (N)			
1	-0.47 [-0.6, -0.3] (37)	-0.61 [-0.8, -0.5] (54)	-0.13 [-0.3, 0.0] (26)
3	-0.59 [-0.8, -0.4] (36)	-0.78 [-1.0, -0.6] (54)	-0.28 [-0.5, -0.1] (26)
6	-0.64 [-0.9, -0.4] (34)	-0.90 [-1.1, -0.7] (54)	-0.25 [-0.7, 0.2] (10)
9	-0.78 [-1.1, -0.5] (21)	-1.04 [-1.2, -0.9] (40)	-
12	-0.74 [-1.1, -0.4] (18)	-0.99 [-1.2, -0.8] (38)	-

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score (erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; N, number of evaluable patients at time point of interest.

Supplementary Table 3. ACR20, ACR50, and ACR70 response rates in the Mexican LTE

study population over time (FAS, no imputation)

| Month | ACR20, % (n/N) [95% CI] | | ACR50, % (n/N) [95% CI] | | ACR70, % (n/N) [95% CI] | |
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
1	64.71 (55/85) [53.6, 74.8]	79.20 (99/125) [71.0, 85.9]	40.00 (34/85) [29.5, 51.2]	52.80 (66/125) [43.7, 61.8]	15.29 (13/85) [8.4, 24.7]	31.20 (39/125) [23.2, 40.1]
3	67.86 (57/84) [56.8, 77.6]	82.11 (101/123) [74.2, 88.4]	53.57 (45/84) [42.4, 64.5]	65.04 (80/123) [55.9, 73.4]	20.24 (17/84) [12.3, 30.4]	34.96 (43/123) [26.6, 44.1]
6	65.48 (55/84) [54.3, 75.5]	81.82 (99/121) [73.8, 88.2]	46.43 (39/84) [35.5, 57.7]	61.16 (74/121) [51.9, 69.9]	29.76 (25/84) [20.3, 40.7]	44.63 (54/121) [35.6, 53.9]
9	70.37 (57/81) [59.2, 80.0]	76.58 (85/111) [67.6, 84.1]	58.02 (47/81) [46.5, 68.9]	55.86 (62/111) [46.1, 65.3]	37.04 (30/81) [26.6, 48.5]	40.54 (45/111) [31.3, 50.3]
12	71.79 (56/78) [60.5, 81.4]	74.53 (79/106) [65.1, 82.5]	51.28 (40/78) [39.7, 62.8]	59.43 (63/106) [49.5, 68.9]	26.92 (21/78) [17.5, 38.2]	46.23 (49/106) [36.5, 56.2]
15	81.08 (60/74) [70.3, 89.3]	79.80 (79/99) [70.5, 87.2]	59.46 (44/74) [47.4, 70.7]	65.66 (65/99) [55.4, 74.9]	28.38 (21/74) [18.5, 40.1]	45.45 (45/99) [35.4, 55.8]
18	74.65 (53/71) [62.9, 84.2]	72.62 (61/84) [61.8, 81.8]	54.93 (39/71) [42.7, 66.8]	60.71 (51/84) [49.5, 71.2]	36.62 (26/71) [25.5, 48.9]	46.43 (39/84) [35.5, 57.7]
21	74.29 (52/70) [62.4, 84.0]	71.23 (52/73) [59.5, 81.2]	55.71 (39/70) [43.3, 67.6]	57.53 (42/73) [45.4, 69.0]	32.86 (23/70) [22.1, 45.1]	46.58 (34/73) [34.8, 58.6]
24	80.30 (53/66) [68.7, 89.1]	74.24 (49/66) [62.0, 84.2]	59.09 (39/66) [46.3, 71.1]	57.58 (38/66) [44.8, 69.7]	36.36 (24/66) [24.9, 49.1]	42.42 (28/66) [30.3, 55.2]
27	77.42 (48/62) [65.0, 87.1]	76.47 (39/51) [62.5, 87.2]	56.45 (35/62) [43.3, 69.0]	64.71 (33/51) [50.1, 77.6]	37.10 (23/62) [25.2, 50.3]	47.06 (24/51) [32.9, 61.5]

30	84.75 (50/59) [73.0, 92.8]	72.22 (26/36) [54.8, 85.8]	72.88 (43/59) [59.7, 83.6]	52.78 (19/36) [35.5, 69.6]	45.76 (27/59) [32.7, 59.3]	44.44 (16/36) [27.9, 61.9]
33	83.05 (49/59) [71.0, 91.6]	79.17 (19/24) [57.9, 92.9]	59.32 (35/59) [45.8, 71.9]	58.33 (14/24) [36.6, 77.9]	37.29 (22/59) [25.0, 50.9]	50.00 (12/24) [29.1, 70.9]
36	78.95 (45/57) [66.1, 88.6]	80.00 (12/15) [51.9, 95.7]	61.40 (35/57) [47.6, 74.0]	66.67 (10/15) [38.4, 88.2]	33.33 (19/57) [21.4, 47.1]	60.00 (9/15) [32.3, 83.7]

ACR, American College of Rheumatology; BID, twice daily; CI, confidence interval; FAS, full analysis set; LTE, long-term extension; N, number of evaluable patients at time point of interest.

Supplementary Table 4. Mean (95% CI) change from baseline in DAS28-4(ESR) and mean (95% CI) change from baseline in HAQ-DI score in the Mexican LTE study population over time (FAS, no imputation)

Month	Change from baseline in DAS28-4(ESR), mean [95% CI] (N)		Change from baseline in HAQ-DI, mean [95% CI] (N)	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
1	-1.74 [-2.0, -1.5] (66)	-2.43 [-2.7, -2.2] (124)	-0.59 [-0.7, -0.4] (85)	-0.63 [-0.8, -0.5] (124)
3	-1.92 [-2.3, -1.6] (67)	-2.77 [-3.0, -2.5] (123)	-0.58 [-0.7, -0.4] (84)	-0.70 [-0.8, -0.6] (123)
6	-1.89 [-2.2, -1.6] (66)	-2.86 [-3.1, -2.6] (121)	-0.62 [-0.8, -0.5] (83)	-0.69 [-0.8, -0.6] (121)
9	-2.19 [-2.5, -1.9] (61)	-2.78 [-3.1, -2.5] (108)	-0.65 [-0.8, -0.5] (80)	-0.63 [-0.8, -0.5] (111)
12	-2.15 [-2.5, -1.8] (60)	-2.90 [-3.2, -2.6] (103)	-0.68 [-0.8, -0.5] (78)	-0.64 [-0.8, -0.5] (104)
15	-2.25 [-2.6, -1.9] (55)	-2.89 [-3.2, -2.6] (98)	-0.65 [-0.8, -0.5] (74)	-0.72 [-0.9, -0.6] (98)
18	-2.21 [-2.6, -1.9] (52)	-2.77 [-3.1, -2.4] (83)	-0.66 [-0.8, -0.5] (69)	-0.67 [-0.9, -0.5] (83)
21	-2.07 [-2.5, -1.7] (53)	-2.61 [-3.0, -2.3] (72)	-0.69 [-0.9, -0.5] (69)	-0.60 [-0.8, -0.4] (72)
24	-2.25 [-2.6, -1.9] (50)	-2.63 [-2.9, -2.3] (66)	-0.68 [-0.8, -0.5] (66)	-0.56 [-0.7, -0.4] (66)
27	-2.33 [-2.7, -1.9] (45)	-3.02 [-3.4, -2.7] (51)	-0.72 [-0.9, -0.6] (62)	-0.57 [-0.8, -0.4] (51)
30	-2.56 [-3.0, -2.1] (42)	-3.06 [-3.5, -2.7] (33)	-0.68 [-0.9, -0.5] (59)	-0.40 [-0.7, -0.1] (36)
33	-2.43 [-2.8, -2.1] (43)	-2.66 [-3.1, -2.2] (24)	-0.81 [-1.0, -0.6] (59)	-0.32 [-0.6, -0.1] (24)

| 36 | -2.49 [-2.9, -2.1] (40) | -2.99 [-3.7, -2.3] (15) | -0.75 [-0.9, -0.6] (57) | -0.39 [-0.8, 0.0] (15) |

BID, twice daily; CI, confidence interval; DAS28-4(ESR), Disease Activity Score (erythrocyte sedimentation rate); FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; LTE, long-term extension; N, number of evaluable patients at time point of interest.

Supplementary Table 5A. Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican Phase 3 study population over time

Month	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Placebo
Change from baseline in hemoglobin (g/dL), mean (SE) (N)			
1	0.15 (0.12) (37)	0.01 (0.09) (54)	-0.13 (0.20) (26)
3	0.19 (0.13) (36)	-0.25 (0.11) (53)	-0.06 (0.21) (25)
6	0.15 (0.16) (41)	-0.13 (0.12) (63)	-0.60 (0.45) (10)
9	0.67 (0.20) (30)	0.06 (0.17) (48)	
12	0.86 (0.22) (28)	0.30 (0.17) (47)	
Change from baseline neutrophil count (10^3/mm^3), mean (SE) (N)			
1	-0.52 (0.38) (37)	-0.84 (0.27) (54)	-0.08 (0.27) (26)
3	-0.73 (0.29) (36)	-0.89 (0.26) (53)	-0.16 (0.25) (25)
6	-0.87 (0.21) (41)	-1.06 (0.23) (63)	-0.01 (0.54) (10)
9	-0.33 (0.34) (30)	-0.82 (0.26) (48)	
12	-0.17 (0.38) (28)	-0.26 (0.30) (47)	
Absolute lymphocyte count (10^3/mm^3), mean (SE) (N)			
0	1.74 (0.10) (37)	1.70 (0.10) (55)	1.84 (0.18) (27)

1	1.82 (0.12) (37)	1.90 (0.12) (54)	1.77 (0.17) (26)
3	1.76 (0.10) (36)	1.73 (0.10) (53)	1.96 (0.17) (25)
6	1.70 (0.11) (41)	1.71 (0.11) (63)	1.72 (0.20) (10)
9	1.83 (0.16) (30)	1.73 (0.11) (48)	
12	1.65 (0.13) (28)	1.37 (0.09) (47)	

BID, twice daily; N, number of evaluable patients at time point of interest; SE, standard error.

Supplementary Table 5B. Mean change from baseline in hemoglobin and neutrophil count, and mean absolute lymphocyte count, in the Mexican LTE study population over time

Month	Change from baseline in hemoglobin (g/dL), mean (SE) (N)		Change from baseline neutrophil count (10^3/mm^3), mean (SE) (N)		Absolute lymphocyte count (10^3/mm^3), mean (SE) (N)	
	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID	Tofacitinib 5 mg BID	Tofacitinib 10 mg BID
0	-	-	-	-	2.00 (0.08) (86)	1.63 (0.06) (126)
1	0.10 (0.12) (85)	0.07 (0.10) (124)	-0.93 (0.20) (85)	-0.75 (0.15) (124)	2.12 (0.07) (85)	1.68 (0.06) (124)
3	-0.09 (0.15) (85)	-0.02 (0.10) (122)	-0.79 (0.17) (84)	-0.56 (0.18) (122)	1.98 (0.07) (84)	1.57 (0.06) (122)
12	0.20 (0.15) (78)	0.11 (0.13) (103)	-1.31 (0.22) (78)	-0.6 (0.19) (103)	1.62 (0.05) (78)	1.4 (0.06) (103)
18	0.48 (0.18) (69)	0.23 (0.13) (83)	-1.17 (0.26) (69)	-0.87 (0.16) (83)	1.51 (0.07) (69)	1.33 (0.06) (83)
24	0.45 (0.21) (66)	0.09 (0.16) (62)	-1.52 (0.21) (66)	-0.80 (0.20) (62)	1.45 (0.07) (66)	1.23 (0.05) (62)
30	0.56 (0.23) (57)	0.03 (0.21) (35)	-1.17 (0.24) (57)	-1.18 (0.34) (35)	1.53 (0.07) (57)	1.11 (0.07) (35)
36	0.28 (0.24) (57)	0.42 (0.57) (11)	-1.37 (0.24) (57)	-0.72 (0.69) (11)	1.40 (0.06) (57)	1.07 (0.11) (11)
42	0.46 (0.20) (54)		-1.24 (0.25) (54)		1.36 (0.06) (54)	
48	0.65 (0.20) (52)		-1.04 (0.29) (52)		1.43 (0.08) (52)	
54	0.66 (0.18) (47)		-1.47 (0.24) (47)		1.34 (0.07) (47)	
60	0.37 (0.22) (43)		-1.12 (0.27) (43)		1.36 (0.09) (43)	

66	0.84 (0.23) (32)	-1.48 (0.31) (32)	1.29 (0.08) (32)
72	0.54 (0.34) (12)	-0.91 (0.46) (12)	1.17 (0.10) (12)

BID, twice daily; LTE, long-term extension; N, number of evaluable patients at time point of interest; SE, standard error.